Preoperative Bevacizumab Does Not Significantly Increase Postoperative Complication Rates in Patients Undergoing Hepatic Surgery for Colorectal Cancer Liver Metastases | Zendy

Susan B. Kesmodel | Zendy; Lee M. Ellis | Zendy; E. Lin | Zendy; George J. Chang | Zendy; Eddie K. Abdalla | Zendy; Scott Kopetz | Zendy; JeanNicolas Vauthey | Zendy; Miguel A. Rodrı́guez-Bigas | Zendy; Steven A. Curley | Zendy; Barry W. Feig | Zendy

Open Access

Preoperative Bevacizumab Does Not Significantly Increase Postoperative Complication Rates in Patients Undergoing Hepatic Surgery for Colorectal Cancer Liver Metastases

Author(s) -

Susan B. Kesmodel,

Lee M. Ellis,

E. Lin,

George J. Chang,

Eddie K. Abdalla,

Scott Kopetz,

JeanNicolas Vauthey,

Miguel A. Rodrı́guez-Bigas,

Steven A. Curley,

Barry W. Feig

Publication year - 2008

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2008.17.7857

Subject(s) - medicine , bevacizumab , colorectal cancer , discontinuation , complication , surgery , neoadjuvant therapy , univariate analysis , chemotherapy , logistic regression , concomitant , multivariate analysis , cancer , breast cancer

Although bevacizumab (BV) increases survival rates when used with chemotherapy (CTX) in patients who have metastatic colorectal cancer (CRC), an increase in wound complications has been observed in patients who undergo surgery while receiving BV. We therefore evaluated whether neoadjuvant BV is associated with an increase in postoperative complications in patients undergoing surgery for CRC liver metastases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research